ASCO Jul 19, 2022 Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium Jun 16, 2022 Janssen Hoping to Bring Tissue-Agnostic Data on Balversa to Regulators Next Year Premium Jun 9, 2022 Sophia Genetics, GE Healthcare Begin DEEP-Lung-IV Data Collection, Technology Integration Premium Jun 9, 2022 Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study Jun 8, 2022 Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show Jun 8, 2022 Oncology Pharmacist Helps Boost Patient Enrollment at Community Practices Engaging in MYLUNG Study Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium Jun 8, 2022 Merus, Elevation Oncology Drugs Show Initial Activity in Lung, Pancreatic Cancers With NRG1 Fusions Premium Jun 7, 2022 African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show Jun 7, 2022 Circulating Tumor DNA Utility in Post-Surgery Stage II Colon Cancer Cemented by New Data Premium Jun 7, 2022 Mirati Hoping to Set Apart Adagrasib in Competitive KRAS-Mutant NSCLC Market With CNS Activity Data Premium Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Jun 6, 2022 Oncologists Debate Suitability of CDK4/6 Inhibitors at ASCO Given Long-Term Ibrance Data Premium Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium Jun 6, 2022 Vectibix Outperforms Avastin in First-Line RAS-Wildtype Left-Sided Colorectal Cancer Premium Jun 6, 2022 Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms Jun 5, 2022 Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor Jun 5, 2022 Rectal Cancer Patient Subset Shows Complete Response to Immunotherapy in Small Study Jun 5, 2022 TROPiCS-02 Trial Sees Progression-Free Survival Edge for Trodelvy-Treated Advanced Breast Cancers Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
